Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan L Cohn

Showing results (101-110 of 183) with videos related to

Pageof 19
Sort By:
Molecular Cancer Therapeutics|January 25, 2019
Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for NeuroblastomaAlexandre Chlenski, Chanyoung Park, Marija Dobratic, et al.
Molecular Cancer Therapeutics|April 14, 2005
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitroMurray D Norris, Janice Smith, Kara Tanabe, et al.
The Lancet. Child & Adolescent Health|January 30, 2018
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trialPedro A de Alarcon, Katherine K Matthay, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidyRochelle Bagatell, Pavlina Rumcheva, Wendy B London, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2016
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapyAraz Marachelian, Ami Desai, Frank Balis, et al.
Cell Reports|May 20, 2014
TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastomaChristopher J Mariani, Aparna Vasanthakumar, Jozef Madzo, et al.
Annals of Surgery|September 12, 2012
A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group studyJed G Nuchtern, Wendy B London, Carol E Barnewolt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2011
Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG projectPaola Angelini, Wendy B London, Susan L Cohn, et al.
Pediatric Blood & Cancer|July 22, 2014
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group projectHolly J Meany, Wendy B London, Peter F Ambros, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2016
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group databaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Pageof 19

Showing results (101-110 of 183) with videos related to

Sort By:
Pageof 19
Molecular Cancer Therapeutics|January 25, 2019
Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for NeuroblastomaAlexandre Chlenski, Chanyoung Park, Marija Dobratic, et al.
Molecular Cancer Therapeutics|April 14, 2005
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitroMurray D Norris, Janice Smith, Kara Tanabe, et al.
The Lancet. Child & Adolescent Health|January 30, 2018
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trialPedro A de Alarcon, Katherine K Matthay, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidyRochelle Bagatell, Pavlina Rumcheva, Wendy B London, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2016
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapyAraz Marachelian, Ami Desai, Frank Balis, et al.
Cell Reports|May 20, 2014
TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastomaChristopher J Mariani, Aparna Vasanthakumar, Jozef Madzo, et al.
Annals of Surgery|September 12, 2012
A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group studyJed G Nuchtern, Wendy B London, Carol E Barnewolt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2011
Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG projectPaola Angelini, Wendy B London, Susan L Cohn, et al.
Pediatric Blood & Cancer|July 22, 2014
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group projectHolly J Meany, Wendy B London, Peter F Ambros, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2016
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group databaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Pageof 19